The FOMC unanimously raised the target range 25 bp to 3.75%–4.00%. Its median path is 4.1% at end-2026 and 4.1% at end-2027, versus June medians of 3.8% and 3.6%. That is a material discount-rate reset, even though long bonds initially welcomed the inflation response. Fed statement · SEP
S&P and Nasdaq futures were +0.6%/+0.7%, and pan-European futures +0.5%. Yet the U.S. 2Y was 4.717% and the 10Y near 5%; the dollar reached a seven-week high. Expensive duration assets remain vulnerable. Reuters, 06:21 UTC context
Semiconductors rebounded 0.6% Wednesday, but after a sharp safety-driven de-rating. NVIDIA's Q2 FY27 revenue rose 106% y/y and Data Center 117%, while the stock remains below its 20-day average. Strong fundamentals do not neutralize 5% yields, capex-financing, China and AI-regulation risks. NVIDIA filing · AI selloff
| Asset | Level | Move / session | Interpretation |
|---|---|---|---|
| S&P 500 | 7,552.14 | −0.44% | Post-Fed reversal; 10 new highs vs 20 new lows. |
| Nasdaq Composite | 25,978.43 | −0.01% | Chips cushioned the index; broader Nasdaq breadth was negative. |
| Dow / Russell 2000 | 51,461.78 / 2,858.81 | −1.21% / −0.40% | Rate-sensitive cyclicals/small caps did not confirm a broad risk-on move. |
| VIX | 17.71 | +2.97% | Higher, but below panic territory. |
| U.S. 2Y / 10Y | 4.717% / ~5.00% | 2Y −1 bp early; 10Y near 5% | Bear-flattening after the hike; discount-rate pressure persists. |
| Dollar index | 100.36 | 7-week high | Hawkish Fed supports USD; headwind to commodities and foreign earnings translation. |
| WTI / Brent | $101.12 / $105.67 | WTI −1.3%; Brent −0.2% early | Still inflationary despite supply-relief pullback; WTI quote via Yahoo, Brent via Reuters. |
| Gold | ~$4,293 spot | +0.7% early | Geopolitical hedge offsets dollar/rate pressure. |
| Nikkei 225 | ~64,000 | +0.3% close | Relief after Fed; BOJ hike is the next risk Friday. |
| Hang Seng / CSI 300 | 24,505 indicative / n.a. | −0.7% / −0.2% early | Still trading at cutoff; not final closes. |
| STOXX 600 / DAX / FTSE | 637.09 / 25,537.75 / 10,688.50 | prior close +0.46% / +0.53% / +0.29% | European cash session had not opened; pan-European futures +0.5%. |
U.S. closes and breadth: Reuters Sept. 16. Treasury official Sept. 16 par yields: U.S. Treasury XML (2Y 4.74%, 10Y 5.01% at official daily fixing). Early cross-asset indications: Reuters Sept. 17. Delayed quote cross-check: Yahoo Finance.
Scores are comparative research judgments, not probabilities. “Confidence” measures evidence quality. Entries require confirmation; there is no instruction to transact at the open.
NASDAQ · Mega-cap · Medium/high risk · Horizon: 3–12+ months
Thesis/catalyst: exceptional revenue and data-center growth, with $108bn Q3 guide; a durable AI platform leader if capex converts to customer cash flow. Counterargument: the stock is below its 20-day average, yields are ~5%, China is excluded from guidance, and customer/financing concentration plus AI-slowdown pressure can compress multiples.
NYSE · Mega-cap pharma · Medium risk · Horizon: 3–12+ months
Thesis/catalyst: diversified incretin franchise and unusually deep next-generation metabolic pipeline; Sept. 28–Oct. 2 EASD offers multiple Phase 2/3 readouts. Counterargument: high expectations are embedded, current price is below 20/50-day averages, retatrutide tolerability deserves scrutiny, and reimbursement/manufacturing/competition can limit economics.
NASDAQ · Small-cap quantum · Very high risk · Horizon: 1–4 weeks
Thesis: severe relative/trend weakness in a loss-making, milestone-driven category while real yields and discount rates rise. Counterargument: government funding, technical milestones or a quantum-sector squeeze can cause violent upside.
NASDAQ · Small-cap quantum/photonics · Extreme risk · Horizon: 1–4 weeks
Thesis: Wednesday's +2.04% bounce did not repair a price below all major moving averages; −67.5% from the 1-year high signals persistent supply. Counterargument: at $8 it is not legally a penny stock, and small-cap narrative rallies can sharply reverse trend.
| Rank / ticker | Classification & horizon | Trigger | Invalidation / risk | Scores C/R/O |
|---|---|---|---|---|
| 1 AMD NASDAQ, mega-cap, high beta | Watch bullish 1–4 weeks | $512.50 is +6.3% above 20-day; require hold above ~$495–500 and semiconductor breadth. Data | Close below 50-day ~$495; AI-capex, valuation and competition risk. | 65 / 73 / 69 |
| 2 AVGO NASDAQ, mega-cap | Reversal watch 1–4 weeks / 3–12 months | Only above ~$360 20-day, preferably ~$381 50-day. Current $339.51 trend is damaged. | New low or failure of AI/custom silicon demand; high-rate sensitivity. Data | 72 / 68 / 66 |
| 3 VRT NYSE, large-cap AI cooling/power | Oversold watch 1–4 weeks | Reclaim ~$259 20-day with volume; current $239.41 is ~36% below 1-year high. | Failure below recent support; capex-cycle, execution and multiple risk. Data | 62 / 75 / 64 |
| 4 IONQ NYSE, speculative mid/small-cap quantum | Speculative watch 3–12+ months | Require price back above ~$39.5–40 plus evidence of 2027 delivery execution and organic, not merely acquired, growth. | Below recent low; cash burn, integration, dilution and roadmap slippage. Filing | 73 / 91 / 61 |
| 5 VKTX NASDAQ, small/mid-cap clinical biotech | Binary watch 3–12+ months | Do not buy trend alone: require verified Phase 3 progress/data and reclaim ~$33–34. | Clinical/tolerability miss, financing/dilution, competition; trial outcomes can gap price. Pipeline | 55 / 88 / 58 |
Bias: cautiously fade opening euphoria unless Nasdaq futures strength survives the first hour with breadth and yields below 5%. The 14:30 CEST U.S. data cluster can reverse premarket indications. Biggest risk: oil/geopolitical headlines. Invalidation: broad advance with falling 2Y/10Y and semis holding gains.
Bias: quality over beta; NVDA/AMD only on technical confirmation, avoid broken quantum charts. Biggest risk: the market prices a faster hiking path. Invalidation: 10Y sustainably below 4.90% plus breadth repair would support more cyclicality.
Bias: AI infrastructure and proven metabolic platforms remain secular leaders, but use staged entries. Biggest risk: capex or clinical economics fail to justify valuation. Invalidation: downward earnings revisions, customer financing stress, or adverse benefit-risk/regulatory evidence.